ABSTRACT
Objective: Febrile neutropenia (FN) is viewed as the most decimating oncological crisis particularly in chemotherapy-incited patients. The primary objective of the study was to identify the total direct expenditure of patients during febrile neutropenia with clinical consequences and the secondary aim was to find out the factors associated with higher cost. Materials and Method: This was a single-centered hospital-based study in the largest and only specialized cancer care centre in Bangladesh in the government sector. This prospective study was done in the inpatients’ department of the National Institute of Cancer Research and Hospital from April 2020 to January 2021. The primary outcome was the out-of-pocket patient payments (adjusted by government subsidy) per FN episode. Univariate analysis and multiple linear regression were conducted to identify the factors associated with higher costs. Results and Discussions: A total of 101 patients were enrolled in the study. The mean (SD) age was 33.49 (±15.79) years. Of the 101 participants, 63.4% were male.Among the patients, 13.9% died during the episode and 86.1% recovered. Having co-morbidities and COVID-19 were associated with an increased risk of death. The mean cost was US$ 999.44 (±499.05) and the mean length of hospital stay was 21.98 (±9.3) days. The longer hospital stay was significantly associated with higher costs. Conclusion: This study will help to ascertain the hospital cost and clinical outcome of FN which ultimately can help in policymaking strategy.